Planting a seed seems like a quaint activity, but the University of Texas at Austin doesn’t do anything small. Its new $10 million UT seed fund is going into incubation soon, thanks to the efforts of Discovery to Impact, the team leading the University’s “research commercialization and innovation efforts.”
Except for its scale, this project is no different from any other seed investment, which inputs capital into a business in the form of a lump sum, in exchange for a portion of the business. In this case, the recipients are “promising new startups built on university-owned intellectual property,” according to a press release. In total, UT Austin estimates that this intellectual property, or research enterprise, totals $800 million, a number it commits to “dramatically expand.”
“By investing in these early-stage companies, we will be addressing a crucial gap in the capital market and enabling development of impactful technologies, while encouraging investors to consider opportunities coming out of the university,” said vice president of business strategies and operations Jim Davis in the release.
Discovery to Impact helps launch startups and stays on board through the many growing pains many startups experience, helping to accelerate “new products, services, solutions and cures.” This means choosing and collaborating with three or four new companies each year, and when divided, the seed does appear rather small: companies can expect no more than a $250,000 investment.
The first seed will be planted in Jurata Thin Film, in order to grow solutions that streamline vaccine and biologic development and distribution worldwide. As many who followed COVID-19 vaccine news are aware, one major problem in distributing a vaccine is keeping it cold and stable. Jurata, based on the work of UT College of Pharmacy professor Maria Croyle, makes “thin films” (look up this keyword to see how unique Croyle’s contribution is) that preserve vaccines for up to three years at room temperature. This is excellent news for communities with fewer resources or more arduous shipping needs.
The company is still relatively young, although not brand-new, having been founded in 2019. Its leadership has more experience; CEO Sheila Mikhail and co-founder Jude Samulski have previously collaborated on Asklepios BioPharmaceutical Inc. (AskBio) and Bamboo Therapeutics Inc.
The UT Seed Fund investment, along with other funding, will help bring about a pilot-scale manufacturing line that can create 1,000 doses of loaded thin films per hour, plus studies to ensure the safety of the formulation under the tongue, inside the cheek, and via intramuscular injection.
“Jurata is very excited to be the first recipient of UT Seed Fund,” said Jurata’s senior director of business development, Megan Livingston. “UT has been extremely supportive of our technology and development, and we look forward to continuing our relationship through this investment.”
A similar seed fund already exists at the University of Texas at Dallas, with larger sums for each business. More information about research at UT Austin is available at utexas.edu.
——
This article originally ran on CultureMap.